title: The combretastatin derivative (Cderiv), a vascular disrupting agent, enables polymeric nanomicelles to accumulate in microtumors.
abstract: A previous study found almost no leakage of polymeric nanomicelles from vessels in microtumors. If such vessels become leaky, sufficient nanomedicines may be delivered to microtumors and large tumors. To create leaky vessels, a combretastatin derivative (Cderiv), a vascular disrupting agent, was used. Via vital microscopy with fluorescein isothiocyanate (FITC)-labeled nanomicelles, the effect of Cderiv pretreatment on changes in micelle extravasation was investigated. Whether such treatment would prolong microtumor retention of micelles was also examined. FITC-albumin was used for comparison. The degree of extravasation from intact vessels in microtumors (rat sarcoma LY80) was extremely low and comparable to that from normal vessels. Cderiv pretreatment (1 or 3 days before administration of FITC-labeled compounds) markedly enhanced extravasation of such nanomicelles and albumin from vessels that survived treatment and had restored blood flow. A high concentration of extravasated macromolecules remained even 24 h later in tissue areas whose microcirculatory function had collapsed. Tumors receiving 10 Gy irradiation 3 days before the macromolecules evidenced gradual removal of extravasated macromolecules, which did not accumulate in those areas, despite extravasation from tumor vessels. Our results strongly suggest that pretreatment with Cderiv is quite effective for maintaining microtumor concentrations of nanomicelles and albumin associated with anticancer or diagnostic drugs.
authors.affiliation: Division of Cancer Control, Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai, 980-0785 Miyagi, Japan. k-hori@idac.tohoku.ac.jp
authors.forename: Katsuyoshi
authors.initials: K
authors.lastname: Hori
authors.forename: Masamichi
authors.initials: M
authors.lastname: Nishihara
authors.forename: Kouichi
authors.initials: K
authors.lastname: Shiraishi
authors.forename: Masayuki
authors.initials: M
authors.lastname: Yokoyama
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D001632:Bibenzyls; D001808:Blood Vessels / Q000503:physiopathology*; D019793:Fluorescein; D016650:Fluorescein-5-isothiocyanate / Q000031:analogs & derivatives; D006439:Hemodynamics; D008297:Male; D009369:Neoplasms / Q000098:blood supply / Q000378:metabolism*; D010087:Oxides / Q000494:pharmacology; D011108:Polymers; D051381:Rats; D012709:Serum Albumin
chemical_list: D000970:Antineoplastic Agents; D001632:Bibenzyls; C518288:FITC-albumin; D010087:Oxides; D011108:Polymers; D012709:Serum Albumin; C040105:combretastatin; D016650:Fluorescein-5-isothiocyanate; D019793:Fluorescein